Chronic simultaneous inducible nitric oxide synthase (iNOS) and peripheral cannabinoid CB1 receptors blockade ameliorates pulmonary hypertension in monocrotaline-induced rat model
Abstract
Background: Pulmonary arterial hypertension (PAH) is a severe multifactorial disease associated with impaired pulmonary hemodynamics, leading to right ventricular (RV) hypertrophy and failure. Induction of inducible nitric oxide synthase (iNOS) and/or activation of cannabinoid CB1 receptor (CB1R) is associated with pro-inflammatory, pro-fibrotic, and pro-hypertrophic effects. Therefore, we tested the effects of chronic simultaneous iNOS/CB1R blockade in a rat model of monocrotaline-induced pulmonary hypertension (MCT-PH).
Methods: Rats were injected with monocrotaline or saline (control) and from day 8 after PH induction they received iNOS inhibitor 1400W, peripheral CB1R antagonist JD5037, their combination or relevant vehicles for 17 days. Invasive and non-invasive hemodynamic assessments, biochemical and histological analyses were conducted. Moreover, the contractions of isolated right ventricular papillary muscles in response to β-adrenoreceptor agonist were analyzed.
Results: 1400W improved MCT-impaired rates in rise/decrease in RV pressure. JD5037 administration reduced MCT-induced increase in mean pulmonary artery pressure (mPAP), RV wall thickness, and improved pulmonary artery Doppler parameters. 1400W + JD5037 combined therapy exerted the most beneficial effects. It reduced RV systolic pressure, mPAP, attenuated RV hypertrophy, with improvement of RV function and blood oxygen saturation. Moreover, it showed anti-inflammatory and anti-remodeling properties. However,…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.